Nestlé To Develop Immunotherapies For Food Allergies
Biopharmaceutical company Enterome has signed a strategic R&D collaboration and license agreement with Nestlé Health Science targeting food allergies and inflammatory bowel disease (IBD).
![](https://trademagazin.cdn.webgarden.io/wp-content/uploads/2022/07/pexels-chokniti-khongchum-2280568-scaled.jpg)
Nestlé, Enterome Collaboration
Enterome is a clinical stage biopharmaceutical company developing immunomodulatory drugs based on its bacterial Mimicry drug discovery platform. As part of the agreement, Enterome will receive €40 million upfront in cash and equity from Nestlé Health Science. It will also be eligible to receive clinical and sales milestone payments for each licensed therapeutic candidate plus royalties on net sales. Enterome will be responsible for leading drug discovery activities and bear related costs up to the investigational new drug (IND) application.
Related news
Recent research: almost half of Hungarians do not use sun protection cream, and moreover, they do not avoid the sun in the midday hours either
According to a recent, representative research, only 8 percent of…
Read more >K&H: carbon dioxide emissions do not decrease by themselves
In the absence of a sustainability strategy and concrete carbon…
Read more >This is how the Hungarian fans spent at the venues of the national team’s matches
The cities of the European Football Championship in Germany devoted…
Read more >More new products
A Hungarian specialist became Danone’s Eastern and Central European sales manager
From this July, Enikő Bolyós organizes and manages the company’s…
Read more >Recent research: almost half of Hungarians do not use sun protection cream, and moreover, they do not avoid the sun in the midday hours either
According to a recent, representative research, only 8 percent of…
Read more >The GVH fined Booking almost HUF 400 million with a record fine
Booking did not fully fulfill its obligations requiring the termination…
Read more >